Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers at UT Southwestern Medical Center found that acetate supplements accelerate tumor growth and metastasis in mice. The study suggests that modulating acetate production could be a key to designing therapies for cancer patients.
Researchers found a genomic marker that could help identify patients most likely to benefit from cabazitaxel, a newer member of the taxane family. The study suggests that cabazitaxel may be more effective sooner in treatment for some patients with prostate cancer.
Researchers discovered a key pathway driving tumour growth in bile duct cancer and found that blocking it can prevent cancer cell growth and shrink tumours. The treatment is already being tested in patients with other cancers and shows promise as a potential breakthrough for this devastating disease.
Researchers at Mayo Clinic have identified Stearoyl-CoA desaturase 1 as an oncogenic enzyme crucial to the survival of anaplastic thyroid carcinoma cells. Inhibiting this molecule has been shown to effectively shut down ATC cell growth and induce cell death.
A team of NUS researchers developed a novel strategy to prevent inflammation-associated cancers by targeting the interaction between FAT10 and MAD2. This approach facilitates the development of cancer drugs with fewer side effects, as it targets specific pathological functions without affecting other physiological functions.
Dartmouth investigators develop new algorithms that employ molecular modeling to optimize deimmunized drug candidates. The approach resulted in highly-active and stable biotherapeutic designs that addressed immunogenic hotspots not easily targeted by earlier methods.
Researchers have developed a new algorithm called Gene Rank (GR) to describe gene connectivity, which can be used for disease prognosis and early cancer detection. GR is based on gene expression data and reflects how well a particular gene is connected to other genes.
A study published in JAMA Oncology found that at least one clinically relevant genomic alteration was present in most samples tested, suggesting a potential for personalized therapy. The research analyzed 200 cancer of unknown primary site (CUP) samples and identified 169 specimens with potentially targetable genomic alterations.
A new approach, called an evolutionary trap, steers cells into one evolutionary path while shutting off others, then knocks out the cell population for good. The strategy may be applied to various clinical scenarios where drug resistance is a problem.
Researchers at the University of Manchester developed heat-activated liposomes with antibody targeting capabilities, showing improved drug delivery to tumour tissue in mice. The combination approach resulted in a moderate improvement in animal survival, offering potential for novel targeted drug delivery strategies.
Researchers at Harvard Medical School and University of Waterloo have discovered a new lethal combination of cancer drugs that can shrink tumors and extend the survival of mice with cancer. The study found that targeting specific protein Hck can kill transitioning cells between non-Cancer Stem Cells (CSCs) and CSCs.
The OHSU Knight Cancer Institute awarded $462,656 to 17 projects statewide to address community-identified needs and decrease the impact of cancer on Oregonians. The funded projects focus on preventing tobacco use among youth, increasing colorectal cancer screening, and developing skin cancer prevention programs.
Franziska Michor's research combines evolutionary biology, mathematics, and clinical research to better understand cancer genesis and treatments. Her work has furnished a precise understanding of drug resistance and led to the development of novel cancer treatment regimens.
Researchers at the University of Cincinnati found that SapC-DOPS can selectively target and kill lung cancer cells while sparing normal cells. The nanovesicle delivery system has shown promising results in animal models and human cell cultures, offering hope for a targeted treatment option for this deadly disease.
A study published in Nature identified axitinib as a promising drug candidate for treating drug-resistant leukemia. The researchers used a novel screening method and partnered with Pfizer to define the mechanism of action, providing new insights into blocking cancer-causing kinases.
A recent UCSF-led study identified YAP as a key driver of resistance to targeted cancer therapies. By suppressing YAP, the researchers found that combination therapies targeting both MEK and YAP pathways can enhance the effectiveness of individual drugs in treating BRAF- and RAS-mutant tumors.
G1 Therapeutics, a UNC-Chapel Hill spinout, has secured $33 million in Series B funding to accelerate clinical development of its lead CDK4/6 inhibitor for cancer treatment. The company aims to develop more effective and less toxic methods to treat patients with cancer.
Two-thirds of primary care health professionals want to widen exemption criteria for long-term conditions and lower or abolish charges altogether. The current system is seen as a barrier that prevents some people from receiving necessary prescriptions.
Researchers have developed a new technique called iontophoresis that delivers high concentrations of chemotherapy directly to tumors, reducing the risk of damaging healthy tissue. This technology has the potential to improve treatment outcomes for cancer patients by allowing for more potent anti-cancer drugs to be used.
Researchers at Dartmouth have found that introducing a specific strain of bacteria into the microenvironment of ovarian cancer tumors can transform tumor cells from suppressors to attackers, sparking a strong anti-tumor immune response. The study's results demonstrate a new potential for treating various types of cancers.
A new research by Dr Alessandra Ghigo found that inhibiting the activity of phosphoinositide 3-kinase gamma (PI3K?) protected mice with hypertension from developing heart failure. The study also showed that a PI3K? inhibitor could synergise with chemotherapy to delay tumour growth and prevent cardiotoxicity.
A University of Colorado study finds alterations in expression of PIK3R3 and PTEN genes in young-adult Ewing Sarcoma, commonly observed in adult tumors. These findings could lead to adapted therapeutic strategies for adult cancers to treat Ewing Sarcoma.
Researchers analyzed data from Medicare and VA patients, revealing that physicians' prescribing decisions are influenced by multiple factors, including patient costs and regional variations. The study highlights the need for improvement in healthcare systems to optimize treatment selection and reduce costs.
Researchers at Dartmouth's Norris Cotton Cancer Center have identified ERBB4 as a driver protein in breast cancers that have developed resistance to HER2 targeted therapies. The discovery suggests that anti-ERBB4 drugs could be highly beneficial for patients who no longer respond to first or second-line treatments.
The Damon Runyon Cancer Research Foundation has awarded over $3.76 million in fellowships and Breakthrough Scientist awards to 15 new recipients, providing them with independent funding to pursue innovative projects. The fellows will focus on novel ideas and approaches to combat cancer.
Scientists have made the largest ever catalogue of biological chimeras available to the public domain. The new database comprises over 29,000 small RNA molecules that originate from different genomic regions, which could reveal useful markers for clinical oncology practice and novel drug targets for cancer treatment.
A comprehensive catalog of genetic mutations has been published for 279 head and neck cancers, revealing distinct genetic profiles for HPV-positive and -negative patients. This finding may lead to the development of targeted therapies and improved outcomes for these cancer types.
A study from Boston Children's Hospital and Dana-Farber Cancer Institute found that an existing epigenetic drug can increase the effectiveness of chemotherapy for patients with non-small-cell lung cancer (NSCLC) who have BRG1 or EGFR mutations. This breakthrough suggests a new approach to precision medicine in cancer treatment.
A new study published in Diabetologia found that cancer patients with diabetes have significantly lower medication adherence rates compared to those without diabetes. The research revealed that the type and stage of cancer had a significant impact on medication adherence, with more advanced cancers resulting in substantially lower rates.
Researchers have discovered a way to eradicate cancer stem cells using antibiotics, opening up the possibility of a new treatment for cancer. The study found that four types of antibiotics eradicated cancer stem cells in every test, including glioblastoma and other aggressive forms of cancer.
Researchers at UMD have developed a technology platform for creating targeted drug and vaccine delivery vehicles using customized soap bubbles. The technology can produce 1,000 doses of vaccines in just 72 hours.
The study found genomic similarities between head and neck cancer genomes and other cancers, including squamous cell lung and cervical cancer. Researchers also identified potential new drug targets and biomarkers for treating HPV-related head and neck cancers.
The GW Cancer Institute will launch a yearlong study to gather key information about barriers encountered by patients with cancer, create evaluation tools for patient navigation at the community level, and translate research findings for practice-based audiences.
Scientists at the University of York found that phenytoin reduces tumour growth and cell proliferation in breast cancer models. The study suggests repurposing antiepileptic drugs as a novel therapy for cancer, worthy of further investigation.
A survey of 364 medical journalists found that direct contact with physicians is the most reliable source of information for creating accurate cancer news. Medical journalists also rely on social media and personal connections to support their research, highlighting the need for responsible healthcare reporting.
Researchers at Ohio State University found that androgen receptor activates different genes when bound to antiandrogens, suggesting new targets for prostate cancer treatment. Antiandrogen response elements were discovered, which activate oncogenes relevant to tumor progression.
A Purdue University study found that a combination of low doses of metformin and gene inhibitor BI2536 can successfully halt the growth of late-stage prostate cancer tumors, potentially prolonging patients' lives. The treatment promotes self-destruction of cancer cells and prevents androgen synthesis.
The Vilcek Foundation has awarded Peter Walter the $100,000 Vilcek Prize in Biomedical Science for his pioneering work on protein transport and stress response. Sun Hur and Rob Knight also received $50,000 Creative Promise Prizes for their innovative research on enzyme reactions and microbial communities.
Researchers found that anti-TB granulomas have abnormal blood vessel networks, similar to solid tumors, which limit drug penetration. Treating these vessels with bevacizumab improved drug delivery and reduced oxygen-starved cells.
Researchers discovered that EBV microRNAs block a key component of the human immune system called interferon response. This finding explains why some cancer therapies fail in certain cases and may lead to new treatments for viral cancers.
Cardiothoracic surgeons are stepping back as vascular specialists play a larger role in managing patients with Type B aortic dissections. Advances in minimally invasive endovascular surgery have driven this shift.
The CUDC-101 clinical trial, conducted at the University of Colorado Cancer Center, demonstrated activity against key drivers of head and neck cancer. In the study, patients with medium- to high-risk head and neck cancer showed significant results after treatment with CUDC-101 combined with radiation and chemotherapy.
Researchers found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The study demonstrates the use of nanotechnology to repurpose existing chemotherapy drugs as effective agents against chemoresistant cancer stem cells.
Scientists at UC San Diego School of Medicine discovered that enzymes believed to promote cancer actually suppress tumors. Correcting a loss-of-function PKC mutation in colon cancer cells reduced tumor growth in mouse models, demonstrating normal PKC activity inhibits cancer.
Researchers identified a genetic mutation that may contribute to tumours becoming resistant to current treatments. The study also found a link between defective copies of the DNA repair gene XRCC2 and platinum-based chemotherapy resistance.
Researchers used denoising autoencoders to effectively extract key biological principles from breast cancer gene expression data, resulting in gene expression features that generalize across studies and represent important clinical factors.
A study at Brown University found that reducing Myc gene activity increased the healthy lifespan of laboratory mice by 15%. The mice exhibited better health and organ function, with reduced signs of aging. The study's findings offer encouragement for developing cancer drugs targeting Myc and potential benefits for human health.
A team of investigators at the University of Calgary has identified potential drug targets for neurocutaneous melanocytosis (NCM), a rare childhood cancer. The study used molecular analysis of patient tumor cells grown in animal models, revealing new insights into the disease's biology and suggesting possible treatments.
Researchers have identified a new potential treatment targeting the alternative lengthening of telomeres (ALT) pathway in cancer cells. Treatment with a small molecule inhibitor suppressed growth and survival of ALT-positive tumor cells.
Researchers found that inactive EGFR is involved in autophagy, a process where cells consume nonessential contents to survive. Cancer cells use this process to thrive under stressful conditions. Combining drugs that block autophagy with those that inactivate EGFR could be an effective way to treat cancers
Cancer experts will discuss how to work together to accelerate progress towards a cure, expand global access to prevention, treatment, and care. The World Economic Forum is the right platform to address the urgent need for bold action.
Researchers have identified genetic markers associated with severe neurological toxicity in patients treated with paclitaxel, a highly effective but toxic chemotherapeutic drug. The study found that specific genetic variants can lead to reduced drug excretion and increased toxicity, allowing for personalized treatment risk assessment.
A 40-year study found sustained community-wide programs in rural Maine reduced hospitalizations and death rates by targeting cardiovascular risk factors. Improvements were seen in hypertension control, cholesterol management, and smoking cessation.
Researchers suggest that the tumor microenvironment could play a significant role in cancer treatment and delivery of nanoparticle-based drugs. They found varying levels of drug delivery between two triple-negative breast cancer tumors, highlighting the importance of personalized medicine and better profiling of tumors.
A phase II clinical trial has demonstrated that sunitinib, an FDA-approved drug, provides unprecedented antitumor activity in thymic carcinoma, a rare and aggressive tumor of the thymus gland. The study found that disease control was achieved in over 90% of patients who had failed chemotherapy.
Researchers at CNIO discovered that Notch genes act as tumour suppressors in bladder cancer, clarifying their role and providing clues for understanding their dual function. The study cautions against using therapeutic strategies based on Notch deactivation due to potential increased risk of developing squamous-type tumours.
A new use of an existing antibody cocktail has been confirmed to provide key information about tumor recurrence in head and neck cancer patients. The ProExC cocktail allows pathologists to differentiate between true pre-neoplasia and reactive biopsies, enabling surgeons to make informed decisions about therapeutic interventions.
A new study found that high-dose testosterone therapy can suppress advanced prostate cancers and reverse resistance to testosterone-blocking drugs. Seven of the 14 men showed a significant decrease in PSA levels, while four stayed on testosterone therapy for up to 24 months with continued low PSA levels.
A phase 2 clinical trial found that a combination of lower-intensity chemotherapy and targeted drug trastuzumab significantly reduced the risk of cancer recurrence in women with small, HER2-positive breast tumors. After three years, 98.7% of participants were alive and free of invasive breast cancer.
A new study suggests that dopamine can prevent the growth of blood vessels in tumors without causing serious side effects, unlike existing anti-angiogenic drugs. Dopamine also prevents low neutrophil counts induced by chemotherapy, making it a potential alternative for gastrointestinal cancer treatment.